Guggenheim Initiates Buy Rating for AtaiBeckley (ATAI) With $11 PT, Cites Leadership in Psychiatry.

sábado, 31 de enero de 2026, 9:11 pm ET1 min de lectura
ATAI--

Guggenheim initiates a Buy rating for AtaiBeckley (ATAI) with an $11 price target, citing the company's leadership in next-generation psychiatry. The firm notes the recent merger with Beckley Psytech and the lead asset BPL-003, which has shown compelling efficacy and durability in Phase IIIb trials for treatment-resistant depression. This positions BPL-003 for efficient clinical adoption and commercial scaling.

Guggenheim Initiates Buy Rating for AtaiBeckley (ATAI) With $11 PT, Cites Leadership in Psychiatry.

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios